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The Editorial on the Research Topic
NK cell-based cancer immunotherapy
Innate and adaptive immunity cooperate to eliminate tumors. However, when infrequent cancer cell 
variants are not destroyed, tumor growth and immunosurveillance enter into a dynamic equilib-
rium until cancer cells evade the immune system, at which point malignancies appear clinically as 
a consequence. Therapies designed to induce potent antitumor responses by harnessing the power 
of the immune system are an appealing strategy to control tumor growth. Natural killer (NK) cells 
are innate lymphocytes that play a pivotal role in host immunity against cancer. The activity of NK 
cells is finely tuned by the balance between the signals that emanate from inhibitory and activating 
receptors. Inhibitory receptors, such as killer-cell immunoglobulin-like receptor (KIR) and CD94/
NK Group 2 member A (NKG2A), recognize human leukocyte (HLA) class I molecules whose 
expression is often altered on tumor cells. NK cells recognize tumor cells by activating receptors, such 
as natural cytotoxicity receptors (NCRs) and NKG2D, which sense the changed expression of their 
ligands on the cancer cell surface. Providing important insights, the past 15 years have witnessed an 
explosion of research into the biology and clinical applications of NK cells. Current NK cell-based 
cancer immunotherapy aims to reverse the tumor-induced NK cell dysfunction that is observed in 
patients with cancer and to increase and sustain NK cell effector functions. Therapies involving NK 
cells may either activate endogenous NK cells or involve transfer of exogenous cells by hematopoietic 
stem cell transplantation (HSCT) or adoptive cell therapy.
In this research topic, we have collected several articles that highlight the exciting potential that 
NK cells exhibit as an effective tool in cancer immunotherapy. We open the research topic with two 
articles that describe NK cell surface receptors involved in the recognition of tumor target cells. 
Chester et al. briefly describe NK-cell–tumor interactions and the three most important mechanisms 
of how NK cells kill target cells, i.e., natural killing, antibody-dependent cell-mediated cytotoxicity 
(ADCC), and death receptor-induced apoptosis, and follow with a description of the best studied 
activating and inhibitory receptors involved in tumor cell recognition, along with the ability of 
agonistic monoclonal antibodies (mAbs) specific for costimulatory molecules, such as CD137 and 
OX40. Horton and Mathew focus their review on NCRs, with a special attention to NKp44 and its 
dual activating and inhibitory function following recognition of different ligands. They suggest that 
NCRs serve as receptors for damage-associated molecular pattern (DAMP) molecules in associa-
tion with HLA class I molecules, heparan sulfate proteoglycans (HSPGs), or other coligands and, 
therefore, regulate NK cell activity. A better understanding of the tumor immunosuppressive micro-
environment is very important to design efficient NK cell-based therapies. Hasmim et al. review the 
cell types within the tumor that are involved in the suppression of NK cells, including M2-polarized 
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and how the microenvironmental hypoxia that is characteristic of 
solid tumors inhibit NK cell functions.
Next, there is a group of articles that provide a general vision 
of how to obtain and harness NK cells to fight tumors. Dahlberg 
et al., Domogala et al., Pittari et al., and Rezvani and Rouce have 
reviewed the different cellular sources and methods to isolate, 
differentiate, genetically engineer, expand, and activate ex vivo 
and in  vivo NK cells, including autologous and allogeneic NK 
cells and NK cell lines. In addition to NK cell lines, sources to 
generate NK cell products include NK cells from peripheral blood 
or from cord blood and NK cells differentiated from CD34+ 
hematopoietic precursors or pluripotent stem cells (embryonic 
stem cells or induced pluripotent stem cells). In general, adoptive 
NK cell-based therapy has been more successful in the treatment 
of hematological tumors than in patients with solid tumors, and 
the use of tools aimed to reverse the immunosuppressive tumor 
microenvironment significantly will improve the efficacy of this 
type of therapy. A cell product termed cytokine-induced killer 
(CIK) cells, which possess phenotypic and functional features of 
both NK cells and T cells, is also described by Pittari et al.
Similar to T cells, genetic manipulation of NK cells is emerging 
as a promising tool to increase their antitumor activity. Chimeric 
antigen receptors (CARs) consist of an extracellular domain, 
generally a small chain variable fragment, specific for a tumor 
antigen that is linked with one or more intracellular domains 
able to induce activation signals. In this study, Hermanson and 
Kaufman extensively review the CAR constructs with different 
intracellular activation domains that have been described, to date, 
in NK cells from several sources, suggesting that depending on 
the tumor type and/or target antigen, different CAR constructs 
may be required for optimal activation of NK cells. Carlsten 
and Childs review the advantages and challenges of methods to 
genetically modify NK cells and give an overview of different 
strategies to reprogram NK cells with the objective to improve 
the persistence and expansion of infused cells, to enhance the 
migration to the tumors, and to improve their cytotoxicity. Cell 
lines, such as NK-92, could be an alternative to NK cells from 
patients or allogeneic donors. They could easily be expanded in 
culture, genetically manipulated, and may represent an off-the-
shelf product ready for use. Klingemann et al. review that NK-92 
is the only cell line that has been studied in clinical trials with 
clinically significant responses and minimal adverse reactions.
In contrast to normal cells, many tumor cells express heat-
shock protein 70 (Hsp70) at the cell surface and get released 
into the circulation. Membrane Hsp70 (mHsp70) correlates 
with high aggressiveness of the tumors. In this research topic, 
Gunther et  al. describe that patients with squamous cell and 
adeno non-small cell lung cancer (NSCLC) exhibited high levels 
of serum Hsp70. Furthermore, they found a positive correlation 
between serum levels of Hsp70 with gross tumor volume and 
an inverse correlation with CD69+/CD94+ NK cells in squamous 
NSCLC, suggesting that activated NK cells somehow may be 
involved in the control of tumor growth. The same group has 
previously found in preclinical studies that NK cells activated 
with a naturally occurring Hsp70 peptide (TKD) and IL-2 are 
able of specifically kill mHsp70-expressing tumors, but not 
mHsp70 negative ones. Here, they summarize a Phase I clinical 
trial of TKD/IL-2-stimulated autologous NK cells with NSCLC 
and describe an ongoing Phase II clinical trial of TKD/IL-2-
stimulated NK cells for the treatment of patients with NSCLC, 
following radiochemotherapy (Specht et al.).
The mechanism of action of many therapeutic mAbs for 
cancer treatment involves, at least partially, ADCC through 
FcγRIIIA/CD16a. Many studies have shown that the clinical 
outcome after treatment of patients with mAbs is correlated 
with polymorphisms at the FCGR3A gene, which encodes for 
FcγRIIIA/CD16a, that affect the binding affinity to mAbs. Wang 
et al. review some of the current therapeutic mAbs that are being 
used in the clinic and strategies that increase their ADCC, such 
as modifying the glycosylation patterns of the mAbs, combining 
them with other mAbs, radiation therapy, matrix metalloproteases 
inhibitors or cytokines, and by designing new molecular entities 
such as immunocytokines and bi-specific antibodies. Cetuximab, 
an anti-epidermal growth factor receptor (EGFR) mAb, exerts 
ADCC against EGFR+ target cells. Kloss et al. show that patients 
with head and neck squamous cell carcinomas (HNSCCs) have 
elevated levels of soluble major histocompatibility complex class I 
chain-related peptide A (sMICA) and transforming growth factor 
beta 1 (TGF-β1) in serum, which are responsible for the impaired 
NK cell effector functions and decreased NKG2D expression. 
They show that cetuximab restores the NK cell-mediated killing 
of sMICA-inhibited patient NK cells against HNSCC cells via 
ADCC and enhances tumor infiltration of NK cells in HNSCC 
tumor spheroids.
Autologous hematopoietic stem cell transplantation 
(autoHSCT) is a therapeutic indication for multiple myeloma or 
malignant lymphoma, and it has been shown that the reconstitu-
tion levels of the NK cell pool after autoHSCT has a prognostic 
value. Jacobs et  al. have studied the phenotype and function 
of NK cells after autoHSCT. They found that CD56++ NK cells 
were the major subset 1–2  days after leukocyte regeneration 
(>1000 leukocytes/μl) and that is characterized by a high expres-
sion of CD57 and KIRs, which is age dependent, and that are able 
to degranulate and produce cytokines after tumor interaction. 
On the other hand, preclinical and clinical data have demonstrated 
that, in the context of haploidentical T-cell-depleted HSCT, 
alloreactive NK cells are able to exert a very important antitu-
mor activity, with no increased incidence of GVDH, and that 
mature alloreactive NK cells can be safely infused into patients. 
The KIR–HLA class I mismatch between donor and recipient in 
the graft versus leukemia (GVL) direction has demonstrated to 
enhance the antitumor activity of NK cells. In this research topic, 
two articles by Lim et al. and Ruggeri et al. review the present and 
future of alloreactive NK cells for tumor treatment, mostly acute 
myeloid leukemia (AML), in the context of allogeneic HSCT and 
infusions of alloreactive purified NK cells. These are emerging as 
safe and potent effectors against tumors.
Based on their expressed pattern of cell surface receptors, 
NK cells are divided in subsets that are able to mediate differ-
ent effector functions and are characterized by distinct homing 
properties. Gismondi et al. have reviewed this issue, suggesting 
that, for improved and more efficient NK cell-based therapies, it 
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is necessary to identify, isolate, expand, and administer NK cell 
subsets that exhibit increased effector functions and have the 
adequate homing capabilities to reach the tumors. Chretien et al., 
with an automated procedure using the FLOCK algorithm and 
a panel of three markers (CD56, CD57, and KIRs), define five 
maturation stages of NK cells from human peripheral blood. By 
analyzing a cohort of healthy volunteers and another cohort of 
patients with AML, they found that the latter displayed marked 
differences compared with healthy donors. Moreover, within the 
AML cohort, it was possible to define three distinct groups of 
patients according to their maturation profiles, which might be 
useful for prognostic purposes. Tarazona et al. have reviewed the 
current knowledge about the role of NK cells on the recognition 
and elimination of melanoma cells and the strategies against 
melanoma based on NK cells. In vitro experiments, in vivo data 
from murine models, and observations from melanoma patients 
indicate that NK cells have a role in the immune response against 
melanoma. NK cell-based therapies against melanoma include, 
among others, modulation of NK cell responses by administra-
tion of cytokines, treatment with checkpoint inhibitors and 
bi-specific antibodies, and by adoptive NK cell therapy with 
autologous or allogeneic NK cells and NK cell lines, genetically 
modified or not.
Finally, we want to express our gratitude to all the authors 
who have contributed to this research topic and to the reviewers 
for their magnificent job. We hope that the reader will find this 
research topic motivating and helpful. We invite you to read the 
following articles and immerse yourself in the interesting world 
of NK cell-based cancer immunotherapy.
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